 David Higgins
Concepts (209)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hepatitis B | 3 | 2023 | 66 | 2.220 |
Why?
| | Pregnancy Complications, Infectious | 2 | 2023 | 440 | 1.120 |
Why?
| | Congenital Abnormalities | 1 | 2026 | 109 | 0.900 |
Why?
| | Genomics | 2 | 2026 | 830 | 0.800 |
Why?
| | Rural Health Services | 1 | 2024 | 138 | 0.760 |
Why?
| | Hepatitis B Vaccines | 1 | 2023 | 43 | 0.760 |
Why?
| | Gonorrhea | 1 | 2023 | 63 | 0.730 |
Why?
| | Chlamydia Infections | 1 | 2023 | 79 | 0.720 |
Why?
| | Sexual Health | 1 | 2023 | 68 | 0.720 |
Why?
| | Physicians, Primary Care | 1 | 2024 | 208 | 0.700 |
Why?
| | Sexually Transmitted Diseases | 1 | 2023 | 168 | 0.660 |
Why?
| | Ventricular Function, Left | 4 | 2025 | 544 | 0.640 |
Why?
| | Pre-Exposure Prophylaxis | 1 | 2023 | 269 | 0.620 |
Why?
| | Mitral Valve Insufficiency | 3 | 2024 | 68 | 0.580 |
Why?
| | Sexual and Gender Minorities | 1 | 2023 | 265 | 0.570 |
Why?
| | Vaccines | 1 | 2023 | 389 | 0.560 |
Why?
| | Vaccination | 5 | 2024 | 1428 | 0.550 |
Why?
| | HIV Infections | 2 | 2023 | 3195 | 0.530 |
Why?
| | Anemia, Iron-Deficiency | 1 | 2017 | 62 | 0.490 |
Why?
| | Neoplasms | 3 | 2026 | 2913 | 0.470 |
Why?
| | Attitude of Health Personnel | 1 | 2024 | 1197 | 0.470 |
Why?
| | Anti-HIV Agents | 1 | 2023 | 912 | 0.460 |
Why?
| | Practice Patterns, Physicians' | 1 | 2024 | 1372 | 0.440 |
Why?
| | Mycobacterium tuberculosis | 5 | 2010 | 318 | 0.440 |
Why?
| | Magnetic Resonance Imaging, Cine | 3 | 2025 | 214 | 0.430 |
Why?
| | Cardiomyopathy, Dilated | 1 | 2017 | 356 | 0.410 |
Why?
| | Tuberculosis, Pulmonary | 3 | 2010 | 127 | 0.410 |
Why?
| | Telemedicine | 1 | 2023 | 967 | 0.410 |
Why?
| | Hepatitis B Surface Antigens | 2 | 2023 | 17 | 0.400 |
Why?
| | Heart Ventricles | 1 | 2017 | 756 | 0.360 |
Why?
| | Interleukin-10 | 3 | 2014 | 311 | 0.340 |
Why?
| | Vitamin D Deficiency | 1 | 2012 | 190 | 0.310 |
Why?
| | Stroke Volume | 3 | 2024 | 655 | 0.300 |
Why?
| | Cross Infection | 1 | 2012 | 260 | 0.290 |
Why?
| | Implants, Experimental | 1 | 2009 | 21 | 0.290 |
Why?
| | Mitral Valve | 3 | 2024 | 95 | 0.290 |
Why?
| | Foreign-Body Reaction | 1 | 2009 | 34 | 0.290 |
Why?
| | Tuberculosis | 3 | 2010 | 284 | 0.280 |
Why?
| | Vitamin D | 1 | 2012 | 404 | 0.280 |
Why?
| | Macrophage Colony-Stimulating Factor | 1 | 2008 | 20 | 0.270 |
Why?
| | Female | 19 | 2026 | 79045 | 0.270 |
Why?
| | Humans | 24 | 2026 | 145783 | 0.260 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2008 | 161 | 0.250 |
Why?
| | Child | 8 | 2026 | 22740 | 0.240 |
Why?
| | Pregnancy | 3 | 2023 | 7216 | 0.230 |
Why?
| | Length of Stay | 1 | 2012 | 1350 | 0.230 |
Why?
| | Edema, Cardiac | 1 | 2025 | 2 | 0.230 |
Why?
| | Takotsubo Cardiomyopathy | 1 | 2025 | 3 | 0.230 |
Why?
| | Intensive Care Units | 1 | 2012 | 924 | 0.230 |
Why?
| | Critical Illness | 1 | 2012 | 900 | 0.220 |
Why?
| | Biocompatible Materials | 1 | 2009 | 429 | 0.220 |
Why?
| | Pandemics | 2 | 2023 | 1711 | 0.210 |
Why?
| | Ventricular Function, Right | 2 | 2024 | 297 | 0.210 |
Why?
| | Mass Screening | 2 | 2023 | 1361 | 0.210 |
Why?
| | Predictive Value of Tests | 3 | 2025 | 2123 | 0.210 |
Why?
| | Information Dissemination | 1 | 2026 | 224 | 0.200 |
Why?
| | United States | 4 | 2026 | 16126 | 0.200 |
Why?
| | Heart Failure | 1 | 2017 | 2326 | 0.200 |
Why?
| | Blood Coagulation Tests | 1 | 2023 | 72 | 0.200 |
Why?
| | Hepatitis B virus | 1 | 2023 | 33 | 0.190 |
Why?
| | Sepsis | 2 | 2022 | 664 | 0.180 |
Why?
| | Platelet Endothelial Cell Adhesion Molecule-1 | 2 | 2014 | 50 | 0.180 |
Why?
| | HIV | 1 | 2023 | 251 | 0.180 |
Why?
| | Ventricular Remodeling | 1 | 2024 | 278 | 0.170 |
Why?
| | Homosexuality, Male | 1 | 2023 | 231 | 0.170 |
Why?
| | Infant, Newborn | 2 | 2023 | 6465 | 0.170 |
Why?
| | Exercise Test | 1 | 2024 | 630 | 0.170 |
Why?
| | Influenza A Virus, H1N1 Subtype | 1 | 2022 | 159 | 0.170 |
Why?
| | Infectious Disease Transmission, Vertical | 1 | 2023 | 194 | 0.170 |
Why?
| | Myocardium | 1 | 2025 | 935 | 0.160 |
Why?
| | Macrophages | 1 | 2008 | 1507 | 0.160 |
Why?
| | Disease Progression | 3 | 2017 | 2865 | 0.150 |
Why?
| | Pneumonia, Aspiration | 2 | 2013 | 16 | 0.150 |
Why?
| | Retrospective Studies | 4 | 2023 | 17330 | 0.150 |
Why?
| | Influenza Vaccines | 1 | 2024 | 534 | 0.150 |
Why?
| | Feasibility Studies | 1 | 2024 | 1115 | 0.150 |
Why?
| | Infant | 2 | 2024 | 10091 | 0.150 |
Why?
| | Echocardiography | 2 | 2024 | 648 | 0.140 |
Why?
| | Chemokines, C | 2 | 2008 | 5 | 0.140 |
Why?
| | Hospitals | 1 | 2023 | 733 | 0.140 |
Why?
| | Male | 12 | 2025 | 73010 | 0.130 |
Why?
| | Deglutition Disorders | 2 | 2013 | 154 | 0.130 |
Why?
| | Ferritins | 1 | 2017 | 70 | 0.130 |
Why?
| | RNA, Small Interfering | 2 | 2010 | 638 | 0.130 |
Why?
| | Antiviral Agents | 1 | 2023 | 769 | 0.130 |
Why?
| | Adult | 7 | 2025 | 40881 | 0.120 |
Why?
| | Enterocolitis, Pseudomembranous | 1 | 2016 | 29 | 0.120 |
Why?
| | Fecal Microbiota Transplantation | 1 | 2016 | 27 | 0.110 |
Why?
| | Transforming Growth Factor beta | 2 | 2009 | 474 | 0.110 |
Why?
| | Magnetic Resonance Imaging | 2 | 2025 | 3916 | 0.110 |
Why?
| | Lung | 5 | 2013 | 4116 | 0.110 |
Why?
| | Tracheostomy | 1 | 1997 | 142 | 0.110 |
Why?
| | Iron | 1 | 2017 | 359 | 0.110 |
Why?
| | Cryopreservation | 1 | 2016 | 113 | 0.110 |
Why?
| | Diarrhea | 1 | 2016 | 193 | 0.110 |
Why?
| | Parents | 1 | 2023 | 1407 | 0.110 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2023 | 1420 | 0.110 |
Why?
| | Cytokines | 4 | 2010 | 2069 | 0.100 |
Why?
| | Colorado | 1 | 2024 | 4556 | 0.100 |
Why?
| | Th1 Cells | 3 | 2010 | 139 | 0.100 |
Why?
| | Middle Aged | 6 | 2025 | 36309 | 0.100 |
Why?
| | Heme Oxygenase (Decyclizing) | 1 | 2013 | 21 | 0.100 |
Why?
| | Primary Health Care | 1 | 2024 | 1737 | 0.100 |
Why?
| | Propranolol | 1 | 2013 | 44 | 0.100 |
Why?
| | Mice | 9 | 2014 | 18355 | 0.100 |
Why?
| | Sialorrhea | 1 | 2013 | 2 | 0.100 |
Why?
| | Brain Neoplasms | 1 | 2022 | 1331 | 0.100 |
Why?
| | Interferon-gamma | 4 | 2010 | 784 | 0.090 |
Why?
| | Reproducibility of Results | 3 | 2025 | 3418 | 0.090 |
Why?
| | Metabolic Diseases | 1 | 2013 | 114 | 0.090 |
Why?
| | Neuromuscular Agents | 1 | 2013 | 46 | 0.090 |
Why?
| | Adrenergic beta-Antagonists | 1 | 2013 | 252 | 0.090 |
Why?
| | Botulinum Toxins, Type A | 1 | 2013 | 60 | 0.090 |
Why?
| | Biomarkers | 2 | 2017 | 4302 | 0.090 |
Why?
| | Surveys and Questionnaires | 1 | 2024 | 6085 | 0.090 |
Why?
| | Confidence Intervals | 1 | 2012 | 330 | 0.080 |
Why?
| | CD4-Positive T-Lymphocytes | 2 | 2008 | 1146 | 0.080 |
Why?
| | Macrophages, Alveolar | 2 | 2014 | 373 | 0.080 |
Why?
| | Critical Care | 1 | 1997 | 702 | 0.080 |
Why?
| | Lymphocyte Activation | 3 | 2010 | 1133 | 0.080 |
Why?
| | Prospective Studies | 3 | 2024 | 8078 | 0.080 |
Why?
| | Pulmonary Fibrosis | 1 | 2014 | 395 | 0.080 |
Why?
| | Follow-Up Studies | 2 | 2017 | 5428 | 0.080 |
Why?
| | Quality of Life | 1 | 2022 | 3211 | 0.080 |
Why?
| | Patient Admission | 1 | 2012 | 220 | 0.080 |
Why?
| | Animals | 11 | 2014 | 38101 | 0.080 |
Why?
| | Transforming Growth Factor beta1 | 1 | 2010 | 177 | 0.080 |
Why?
| | Cause of Death | 1 | 2012 | 472 | 0.080 |
Why?
| | Aged | 6 | 2025 | 26217 | 0.070 |
Why?
| | Child, Preschool | 1 | 2024 | 11868 | 0.070 |
Why?
| | Lymphocyte Subsets | 1 | 2009 | 78 | 0.070 |
Why?
| | Hemorrhage | 1 | 2014 | 822 | 0.070 |
Why?
| | Bone Marrow Cells | 1 | 2010 | 322 | 0.070 |
Why?
| | Risk Factors | 1 | 2023 | 10919 | 0.070 |
Why?
| | Prognosis | 1 | 2017 | 4330 | 0.070 |
Why?
| | Proportional Hazards Models | 1 | 2012 | 1330 | 0.070 |
Why?
| | Oximetry | 1 | 2009 | 125 | 0.070 |
Why?
| | Lymphocyte Culture Test, Mixed | 1 | 2008 | 49 | 0.070 |
Why?
| | Immunohistochemistry | 2 | 2009 | 1723 | 0.070 |
Why?
| | Chronic Disease | 3 | 2010 | 1812 | 0.070 |
Why?
| | Flow Cytometry | 2 | 2009 | 1165 | 0.070 |
Why?
| | Cell Count | 1 | 2008 | 319 | 0.060 |
Why?
| | Monocytes | 1 | 2010 | 539 | 0.060 |
Why?
| | Granuloma | 1 | 2007 | 97 | 0.060 |
Why?
| | T-Lymphocytes, Cytotoxic | 1 | 2007 | 177 | 0.060 |
Why?
| | National Cancer Institute (U.S.) | 1 | 2026 | 54 | 0.060 |
Why?
| | Immune Tolerance | 1 | 2009 | 385 | 0.060 |
Why?
| | Histocompatibility Antigens Class II | 1 | 2008 | 364 | 0.060 |
Why?
| | Observer Variation | 2 | 2024 | 357 | 0.060 |
Why?
| | Mice, Inbred C57BL | 4 | 2010 | 5992 | 0.060 |
Why?
| | Patient Discharge | 1 | 2012 | 995 | 0.060 |
Why?
| | Mice, Knockout | 2 | 2010 | 3130 | 0.060 |
Why?
| | Fibrosis | 2 | 2023 | 561 | 0.060 |
Why?
| | Prevalence | 1 | 2012 | 2875 | 0.050 |
Why?
| | Adolescent | 1 | 2024 | 22577 | 0.050 |
Why?
| | Dendritic Cells | 1 | 2008 | 501 | 0.050 |
Why?
| | Pneumonia | 1 | 2010 | 636 | 0.050 |
Why?
| | Asymptomatic Diseases | 1 | 2024 | 104 | 0.050 |
Why?
| | Treatment Outcome | 3 | 2016 | 11794 | 0.050 |
Why?
| | Cells, Cultured | 2 | 2008 | 4151 | 0.050 |
Why?
| | Sensitivity and Specificity | 1 | 2008 | 2000 | 0.050 |
Why?
| | Lung Diseases, Interstitial | 1 | 2009 | 664 | 0.050 |
Why?
| | Cardiac Volume | 1 | 2001 | 14 | 0.040 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2007 | 923 | 0.040 |
Why?
| | Phenotype | 1 | 2008 | 3170 | 0.040 |
Why?
| | Precision Medicine | 1 | 2023 | 461 | 0.040 |
Why?
| | Case-Control Studies | 1 | 2025 | 3634 | 0.030 |
Why?
| | Transcriptome | 1 | 2022 | 1042 | 0.030 |
Why?
| | Gene Expression Profiling | 1 | 2022 | 1777 | 0.030 |
Why?
| | Monitoring, Physiologic | 1 | 1997 | 289 | 0.030 |
Why?
| | Hemosiderin | 1 | 2014 | 2 | 0.030 |
Why?
| | Bleeding Time | 1 | 2014 | 5 | 0.030 |
Why?
| | Time Factors | 1 | 2025 | 7134 | 0.030 |
Why?
| | Fibrin | 1 | 2014 | 84 | 0.020 |
Why?
| | Mice, Inbred Strains | 1 | 2014 | 396 | 0.020 |
Why?
| | Enzyme Induction | 1 | 2013 | 88 | 0.020 |
Why?
| | Myofibroblasts | 1 | 2014 | 149 | 0.020 |
Why?
| | Diagnosis, Differential | 1 | 1997 | 1512 | 0.020 |
Why?
| | Movement Disorders | 1 | 2013 | 69 | 0.020 |
Why?
| | Recurrence | 1 | 2016 | 1139 | 0.020 |
Why?
| | Injections | 1 | 2013 | 199 | 0.020 |
Why?
| | Intubation, Gastrointestinal | 1 | 2013 | 81 | 0.020 |
Why?
| | Drug Administration Schedule | 1 | 2013 | 782 | 0.020 |
Why?
| | Ultrasonography, Interventional | 1 | 2013 | 166 | 0.020 |
Why?
| | Disease Models, Animal | 2 | 2014 | 4568 | 0.020 |
Why?
| | Patient Care Team | 1 | 1997 | 697 | 0.020 |
Why?
| | Double-Blind Method | 1 | 2016 | 2064 | 0.020 |
Why?
| | Butylated Hydroxytoluene | 1 | 2010 | 37 | 0.020 |
Why?
| | Infrared Rays | 1 | 2009 | 24 | 0.020 |
Why?
| | Interleukin-4 | 1 | 2010 | 207 | 0.020 |
Why?
| | Cell Polarity | 1 | 2010 | 137 | 0.020 |
Why?
| | Mice, Mutant Strains | 1 | 2009 | 302 | 0.020 |
Why?
| | Survival Rate | 1 | 2013 | 2094 | 0.020 |
Why?
| | Patient Satisfaction | 1 | 2013 | 712 | 0.020 |
Why?
| | Early Diagnosis | 1 | 2009 | 251 | 0.020 |
Why?
| | Tissue Distribution | 1 | 2008 | 335 | 0.020 |
Why?
| | Aerosols | 1 | 2008 | 146 | 0.020 |
Why?
| | Gene Silencing | 1 | 2008 | 202 | 0.020 |
Why?
| | Rats, Sprague-Dawley | 1 | 2013 | 2525 | 0.020 |
Why?
| | Administration, Inhalation | 1 | 2008 | 571 | 0.020 |
Why?
| | Sex Factors | 1 | 2013 | 2110 | 0.020 |
Why?
| | Rats | 1 | 2013 | 5585 | 0.010 |
Why?
| | Oxygen | 1 | 2009 | 981 | 0.010 |
Why?
| | Aged, 80 and over | 1 | 2016 | 8347 | 0.010 |
Why?
| | Hospitalization | 1 | 2013 | 2461 | 0.010 |
Why?
| | Cohort Studies | 1 | 2013 | 6033 | 0.010 |
Why?
| | Phantoms, Imaging | 1 | 2001 | 159 | 0.010 |
Why?
| | T-Lymphocytes | 1 | 2008 | 1998 | 0.010 |
Why?
| | Swine | 1 | 2001 | 826 | 0.010 |
Why?
|
|
Higgins's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|